A federal judge in Texas on Wednesday upheld a determination by the U.S. FDA in August 2024 that a nationwide shortage of Eli Lilly’s (NYSE:LLY) blockbuster weight loss med Zepbound (tirzepatide) was over.
Following that determination, the drug compounding industry led
